SUMMARY OF THE DISCLOSURE

[0007] One aspect of the disclosure provides methods for treating cancer in a subject. Such methods include administering to the subject a therapeutically effective amount of a therapeutically effective amount of a PRMT5 inhibitor with a therapeutically effect amount of a taxane.

[0007a] In one aspect of the present disclosure, there is provided a use of a protein arginine N-methyl transferase 5 (PRMT5) inhibitor in the manufacture of a medicament for treating cancer in a subject, wherein a therapeutically effective amount of a taxane and a therapeutically effective amount of the PRMT5 inhibitor are to be administered to the subject, wherein the PRMT5 inhibitor is a compound of the formula  or a pharmaceutically acceptable salt thereof.

[0008] In particular embodiments, the taxane as otherwise described herein is docetaxel.

[0009] Also provided herein is a method for treating cancer in a subject in need thereof. Such methods include determining that the cancer is associated with MTAP homozygous deletion (e.g., an MTAP-associated cancer).

[0010] These and other features and advantages of the present invention will be more fully understood from the following detailed description taken together with the accompanying claims. It is noted that the scope of the claims is defined by the recitations therein and not by the specific discussion of features and advantages set forth in the present description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] The accompanying drawings are included to provide a further understanding of the methods of the disclosure, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s) of the disclosure and, together with the description, serve to explain the principles and operation of the disclosure.

[0012] Figure 1 illustrates the results of Example 1, wherein MRTX1719 (PO, QD), docetaxel (IP Q7D) or the combination were dosed to mice bearing H1650 xenograft tumors (n=5/cohort). Data shown as mean +/- SEM.

[0013] Figure 2 illustrates the results of Example 2, wherein MRTX1719 (oral, QD), docetaxel (IP Q7D) or the combination were dosed to mice bearing H2228 xenograft tumors (n=5/cohort). Data shown as mean +/- SEM.

[0014] Figure 3 illustrates the results of Example 3, wherein MRTX1719 (oral, QD), docetaxel (IP Q7D) or the combination were dosed to mice bearing A549 xenograft tumors (n=5/cohort). Data shown as mean +/- SEM.

[0015] Figure 4 illustrates the results of Example 4, wherein MRTX1719 (oral, QD), docetaxel (IP Q7D) or the combination were dosed to mice bearing HCC4006 xenograft tumors (n=5/cohort). Data shown as mean +/- SEM.

[0016] Figure 5 illustrates the results of Example 5, wherein MRTX1719 (oral, QD), docetaxel (IP Q7D) or the combination were dosed to mice bearing SW1573 xenograft tumors (n=5/cohort). Data shown as mean +/- SEM.